Table 3 Laboratory data of siblings II-1 and II-2 at initial presentation, at relapse of disease requiring ofatumumab infusion and at follow-up 8 months after ofatumumab infusion
Investigations | Patient II-1 (reference range) | Patient II-2 (reference range) | ||||
|---|---|---|---|---|---|---|
At presentation | At relapse | 8 months after ofatumumab | At presentation | At relapse | 8 months after ofatumumab | |
FBC × 10^12/L (RR 4.00–5.20) | 3.88 | 3.92 | 4.76 | 3.6 | 3.01 | 5.26 |
Hb g/L (RR 115–145) | 96 | 102 | 118 | 97 | 73 | 128 |
Platelets × 10^9/L (RR 150–450) | 85 | 5 | 209 | 13 | 63 | 397 |
WCC × 10^9/L (RR 0.0–10.0) | 5.94 | 6.54 | 6.58 | 9.60 | 2.78 | 7.83 |
Lymphocytes × 10^9/L (1.5–7.0) | 1.79 | 1.69 | 1.65 | 1.70 | 0.48 | 1.86 |
Neutrophils × 10^9/L (RR 1.5–8.0) | 2.17 | 4.20 | 1.83 | 1.01 | 2.23 | 4.90 |
CD 19 lymphocyte subset % | 21.0 | not assessed | 0.0 | 25.0 | 23.7 | 0.5 |
CD 3 lymphocyte subset % | 73.0 | not assessed | 97.5 | 65.0 | 83.0 | 96.0 |
CD 16+ CD 56+ lymphocyte subset % | 4.0 | not assessed | 1.7 | 8.0 | 5.0 | 0.7 |
CD 3+ CD 56+ lymphocyte subset % | 0.2 | not assessed | not assessed | 0.2 | 0.8 | not assessed |
CD 3+ CD4+ lymphocyte subset % | 46.0 | not assessed | 49.7 | 32.0 | 38.0 | 41.5 |
CD 3+ CD 8+ lymphocyte subset % | 21.0 | not assessed | 40.6 | 37.0 | 37.0 | 42.2 |
ESR mm/hr. (RR 0–10) | 128 | 132 | 50 | 130 | 75 | 1 |
CRP mg/L (RR < 20) | 21 | 19 | < 5 | 28 | 21 | < 5 |
Urea | 3.4 | 3.9 | 3.4 | 4.8 | 7.8 | 4.1 |
Creatinine umol/L (RR 28–57) | 36 | 25 | 40 | 33 | 83 | 52 |
Urine creatinine mmol/L | 3.4 | 1.5 | 3.5 | 2.8 | 1.1 | 0.5 |
Urine albumin/creatinine ratio mg/mmol (RR 0.2–4.5) | 1.5 | 5.3 | 3.1 | 8.9 | 1.1 | not assessed |
Urine NAG/creatinine ratio units/mmol (RR 2–20) | not assessed | not assessed | 4 | not assessed | 67 | 74 |
Urine retinol binding protein ug/L | not assessed | not assessed | 39 | not assessed | not assessed | 161 |
Urine retinol/creatinine ratio ug/mmol (RR 5–41) | not assessed | not assessed | 11 | not assessed | not assessed | 85 |
ANA | 1:1280 | not assessed | 1:640 | Negative | not assessed | not assessed |
Anti-DNA IU/ml (RR 0–9.9) | 65 | 66 | 16 | 43 | 16 | 4.8 |
IgG G/L (RR 5.4–16.1) | 16.8 | 22.3 | 7.66 | 21.9 | 18.5 | 7.12 |
IgA G/L (RR 0.5–2.4) | 2.19 | 2.35 | 1.15 | 2.69 | 3.34 | 1.72 |
IgM G/L (RR 0.5–1.8) | 1.63 | 1.31 | 0.35 | 2.90 | 2.36 | 0.86 |
C3 G/L (RR 0.75–1.65) | 0.83 | 0.41 | 1.51 | 0.64 | 0.91 | 1.37 |
C4 G/L (RR 0.14–0.54) | 0.10 | 0.03 | 0.19 | 0.08 | 0.15 | 0.29 |